Immunization-Associated Corneal Transplantation Rejection

Cornea ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Edward H. Lee ◽  
Jennifer Y. Li
Keyword(s):  
Corneal Transplantation ◽  
Transplantation Rejection

Kaempferol Alleviates Corneal Transplantation Rejection by Inhibiting NLRP3 Inflammasome Activation and Macrophage M1 Polarization via Promoting Autophagy

2021 ◽  
Author(s):  
Huiwen Tian ◽  
Shumei Lin ◽  
Jing Wu ◽  
Ming Ma ◽  
Jian Yu ◽  
...  
Keyword(s):  
Nlrp3 Inflammasome ◽  
Macrophage Polarization ◽  
Corneal Transplantation ◽  
Inflammasome Activation ◽  
M1 Polarization ◽  
Nlrp3 Inflammasome Activation ◽  
M1 Macrophage ◽  
Transplantation Rejection

Abstract Corneal transplantation rejection remains a major threat to the success rate in high-risk patients. Given the many side effects presented by traditional immunosuppressants, there is an urgency to clarify the mechanism of corneal transplantation rejection and to identify new therapeutic targets. Kaempferol is a natural flavonoid that has been proven in various studies to possess anti-inflammatory, antioxidant, anticancer, and neuroprotective properties. However, the relationship between kaempferol and corneal transplantation remains largely unexplored. To address this, both in vivo and in vitro, we established a model of corneal allograft transplantation in Wistar rats and an LPS-induced inflammatory model in THP-1 derived human macrophages. In the transplantation experiments, we observed an enhancement in the NLRP3 / IL-1 β axis and in M1 macrophage polarization post-operation. In groups to which kaempferol intraperitoneal injections were administered, this response was effectively reduced. However, the effect of kaempferol was reversed after the application of autophagy inhibitors. Similarly, in the inflammatory model, we found that different concentrations of kaempferol can reduce the LPS-induced M1 polarization and NLRP3 inflammasome activation. Moreover, we confirmed that kaempferol induced autophagy and that autophagy inhibitors reversed the effect in macrophages. In conclusion, we found that kaempferol can inhibit the activation of the NLRP3 inflammasomes by inducing autophagy, thus inhibiting macrophage polarization, and ultimately alleviating corneal transplantation rejection. Thus, our study suggests that kaempferol could be used as a potential therapeutic agent in the treatment of allograft rejection.

Targeting NF‐κB c‐Rel in regulatory T cells to treat corneal transplantation rejection

2021 ◽  
Author(s):  
Jiang Bian ◽  
Ting Wang ◽  
Jijun Sun ◽  
Xiaozhen He ◽  
Zhijiao Wu ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Corneal Transplantation ◽  
Transplantation Rejection

scholarly journals MicroRNA-122 ameliorates corneal allograft rejection through the downregulation of its target CPEB1

2017 ◽  
Vol 3 (1) ◽  
Author(s):  
Ting Wang ◽  
Fengjie Li ◽  
Wenwen Geng ◽  
Qingguo Ruan ◽  
Weiyun Shi
Keyword(s):  
Allograft Rejection ◽  
Transplant Rejection ◽  
Corneal Transplantation ◽  
Human Organ ◽  
Corneal Allograft ◽  
Corneal Graft Rejection ◽  
Transplantation Rejection ◽  
Element Binding Protein ◽  
Induced Apoptosis ◽  
Corneal Allograft Rejection

Abstract Transplant rejection is a major cause of corneal transplantation failure. MicroRNAs (miRNAs) are a family of small RNAs that regulates gene expression in a sequence-specific manner. miRNAs have recently been shown to have important roles in human organ transplantation, but reports of miRNAs directly associated with corneal transplantation rejection remain limited. To investigate the role of miRNAs during corneal allograft rejection, we established a mouse penetrating keratoplasty model and used microarrays to screen for differentially expressed miRNAs. Our results revealed that the expression of miR-122 was significantly decreased in the allogeneic group. Consistent with this result, the expression of cytoplasmic polyadenylation element-binding protein-1 (CPEB1), a direct target of miR-122, was significantly increased. Further analysis demonstrated that miR-122 inhibited inflammatory cytokine-induced apoptosis in corneal keratocytes through the downregulation of its target CPEB1. We also found that increased miR-122 expression significantly reduced the risk of corneal transplantation rejection. Thus, our results indicate that miR-122 is an important miRNA associated with corneal graft rejection and can be used as a therapeutic target for the prevention of immune rejection after keratoplasty.

Role of ABO and Lewis Blood Group Antigens in Donor-Recipient Compatibility of Corneal Transplantation Rejection

Ophthalmology ◽  
1997 ◽  
Vol 104 (3) ◽  
pp. 508-512 ◽  
Author(s):  
Raynald Roy ◽  
Béatrice Des Marchais ◽  
Richard Bazin ◽  
Hélène M. Boisjoly ◽  
Ide Dubé ◽  
...  
Keyword(s):  
Blood Group ◽  
Corneal Transplantation ◽  
Blood Group Antigens ◽  
Lewis Blood Group ◽  
Transplantation Rejection

Outcome of Corneal Transplantation Rejection

Cornea ◽  
2001 ◽  
Vol 20 (4) ◽  
pp. 350-353 ◽  
Author(s):  
Hélène G. Naacke ◽  
Vincent M. Borderie ◽  
Tristan Bourcier ◽  
Olivier Touzeau ◽  
Mihnea Moldovan ◽  
...  
Keyword(s):  
Corneal Transplantation ◽  
Transplantation Rejection

Therapeutic Plasma Exchange Application in Children Requires Individual Decision

2020 ◽  
Author(s):  
Gürkan Atay ◽  
Demet Demirkol
Keyword(s):  
Plasma Exchange ◽  
Vascular Access ◽  
Pediatric Patients ◽  
Demyelinating Disease ◽  
Pediatric Intensive Care ◽  
Therapeutic Plasma Exchange ◽  
Transplantation Rejection ◽  
Access Problems ◽  
Uremic Syndrome

AbstractTherapeutic plasma exchange (TPE) is a treatment administered with the aim of removing a pathogenic material or compound causing morbidity in a variety of neurologic, hematologic, renal, and autoimmune diseases. In this study, we aimed to assess the indications, efficacy, reliability, complications, and treatment response of pediatric patients for TPE. This retrospective study analyzed data from 39 patients aged from 0 to 18 years who underwent a total of 172 TPE sessions from January 2015 to April 2018 in a tertiary pediatric intensive care unit. Indications for TPE were, in order of frequency, macrophage activation syndrome (28.2%, n = 11), renal transplantation rejection (15.4%, n = 6), liver failure (15.4%, n = 6), Guillain–Barre's syndrome (15%, n = 6), hemolytic uremic syndrome (7.7%, n = 3), acute demyelinating disease (7.7%, n = 3), septic shock (5.1%, n = 2), and intoxication (5.1%, n = 2). No patient had any adverse event related to the TPE during the procedure. The TPE session was ended prematurely in one patient due to insufficient vascular access and lack of blood flow (2.6%). In the long term, thrombosis due to the indwelling central catheter occurred (5.1%, n = 2). TPE appears to be an effective first-stage or supplementary treatment in a variety of diseases, may be safely used in pediatric patients, and there are significant findings that its area of use will increase. In experienced hands and when assessed carefully, it appears that the rate of adverse reactions and vascular access problems may be low enough to be negligible.

Sign in / Sign up

Export Citation Format

Share Document